EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis

Juan Eduardo Resendiz-Galvan iD, Prerna R Arora iD, Rohan V Lokhande, Zarir F Udwadia, Camilla Rodrigues, Amita Gupta, Jeffrey A Tornheim iD, Paolo Denti iD, Tester F Ashavaid iD, The MDR-TB MUKT and Indo-South Africa Study Teams, MDR-TB MUKT and Indo-South Africa Study Teams

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00101-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Juan Eduardo Resendiz-Galvan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Cycloserine, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, FIC NIH HHS, NIH/NIAID National Institute of Allergy and Infectious Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cycloserine is recommended for inclusion in regimens for multidrug-resistant tuberculosis (MDR-TB). Its efficacy is time dependent and relies on the concentration remaining above the minimum inhibitory concentration (MIC); however, there is a concentration-dependent risk of neurotoxicity. Limited pharmacokinetic (PK) data are available in individuals of Indian origin, despite the high burden of MDR-TB in India. We enrolled adults and adolescents receiving cycloserine for MDR-TB at a tertiary hospital in Mumbai, India, in a prospective cohort. Total daily doses ranged from 500 to 750 mg, and participants underwent serial PK sampling on multiple visits starting 1 month after treatment initiation. PK data were analyzed using non-linear mixed-effect modeling. A total of 180 participants (117 females) were enrolled, with a median age of 27 years (interquartile range [IQR] 21–35), weight of 56.0 kg (IQR 46.0–65.9), and fat-free mass of 38.6 kg (IQR 32.3–47.1). Cycloserine PK was best described by a one-compartment model with first-order elimination and transit compartment absorption. Allometric scaling by fat-free mass provided the best adjusment for body size. Serum creatinine improved the model fit and allowed separate estimation of renal and non-renal clearances, whose typical values were 0.589 and 0.901 L/h, respectively. Simulations showed median exposure of 308 mg·h/L after 250 mg twice daily (BID), which is lower than reported in literature. Monte Carlo simulations suggested that doses of 500 or 750 mg BID are required to reach efficacy targets of ≥30% and ≥64% time within dose interval above MIC. The reasons behind the low exposure identified in this Indian population require further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CycloserineTuberculosis, Multidrug-ResistantAntitubercular AgentsHumansFemaleAdultMaleIndiaAdolescentProspective StudiesMicrobial Sensitivity TestsYoung Adult

Stichwörter der Autor:innen

MDR-TBNONMEMcycloserinepharmacokineticspharmacometrics

Substanzen

CycloserineAntitubercular Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Research Laboratories, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
  • Center for Infectious Diseases in India, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Juan Eduardo Resendiz-Galvan, Prerna R Arora, Jeffrey A Tornheim, Paolo Denti, Tester F Ashavaid

Förderung

  • NIAID NIH HHS
  • FIC NIH HHS
  • NIH/NIAID National Institute of Allergy and Infectious Disease

Zitieren

APA

Resendiz-Galvan, J. E., Arora, P. R., Lokhande, R. V., Udwadia, Z. F., Rodrigues, C., Gupta, A., Tornheim, J. A., Denti, P., Ashavaid, T. F., The MDR-TB MUKT and Indo-South Africa Study Teams, & MDR-TB MUKT and Indo-South Africa Study Teams (2025). Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00101-25

Vancouver

Resendiz-Galvan JE, Arora PR, Lokhande RV, Udwadia ZF, Rodrigues C, Gupta A, et al. Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00101-25

BibTeX
@article{ResendizGalvan2025,
  author = {Resendiz-Galvan, Juan Eduardo and Arora, Prerna R and Lokhande, Rohan V and Udwadia, Zarir F and Rodrigues, Camilla and Gupta, Amita and Tornheim, Jeffrey A and Denti, Paolo and Ashavaid, Tester F and The MDR-TB MUKT and Indo-South Africa Study Teams, The MDR-TB MUKT and Indo-South Africa Study Teams and MDR-TB MUKT and Indo-South Africa Study Teams, MDR-TB MUKT and Indo-South Africa Study Teams},
  title = {Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00101-25}
}
Kostenlos starten →